Stephen F. Betz - Jul 10, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jul 10, 2024
Transactions value $
-$145,650
Form type
4
Date filed
7/12/2024, 04:30 PM
Previous filing
Jun 26, 2024
Next filing
Jul 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$146K -3K -3.68% $48.55 78.6K Jul 10, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $48.55 per share. The range of sales prices on the transaction date was $48.63 to $48.46 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 Includes 968 shares acquired under the Issuer's Employee Stock Purchase Plan.